Understanding US addiction physicians' low rate of naltrexone prescription
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Naltrexone was approved by the US Food and Drug Administration (FDA) in December 1994. Although it is one of only two medications for alcohol rehabilitation approved in the US, naltrexone is not frequently prescribed. This paper examines the factors limiting physicians' use of naltrexone. Data were collected through a survey of US physician members of two addiction medicine professional associations. Logistic regression analysis was conducted with the dependent variable being any prescription of naltrexone. Independent variables consisted of physician practice characteristics, physician ratings of naltrexone's attributes (e.g. efficacy), physicians' patient characteristics, and physicians' exposure to information about naltrexone. On average, addiction medicine physicians prescribed naltrexone to 13% of their alcoholism patients. The two main self-reported reasons why physicians did not prescribe the medication to more patients were that patients refused to take the medication or comply with prescribing regimes (23%), and that patients could not afford the medication (21%). Multivariate results indicated that physician perceptions of naltrexone's effectiveness and safety were significantly associated with prescribing. Physicians who had more exposure to information about the product (e.g. by reading more journal articles about naltrexone) were more likely to prescribe it. In summary, multiple factors are contributing to the relatively low naltexone prescription rate.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A view of addiction as a disease is justified, because it is beneficial: a failure to diagnose addiction drastically increases the risk of a failure to treat it [20].”
From Addiction as a brain disease revised: why it still matters, and the need for consilience (2021) · doi:10.1038/s41386-020-00950-y · cites this paper as [20]
Citations
Cites
RUBIN, D. B. (1976) · Biometrika · doi:10.1093/biomet/63.3.581 · Cited by 9,925
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Naltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487
Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?
Wazana, A. (2000) · JAMA · doi:10.1001/jama.283.3.373 · Cited by 1,415
Design Sensitivity: Statistical Power for Experimental Research.
Eliason, S. R., & Lipsey, M. W. (1991) · Contemporary Sociology · doi:10.2307/2072167 · Cited by 1,040
Design Sensitivity: Statistical Power for Experimental Research.
Lachenbruch, P. A., & Lipsey, M. W. (1990) · Journal of the American Statistical Association · doi:10.2307/2289636 · Cited by 782
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta‐Analysis
Kranzler, H. R., & Van Kirk, J. (2001) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2001.tb02356.x · Cited by 390
The pharmacological treatment of alcohol dependence.
Swift, R. M. (1997) · PubMed · Cited by 372
Cited by
Garbutt, J. C., Kranzler, H. R., O’Malley, S. S., Gastfriend, D. R., Pettinati, H. M., Silverman, B. L., Loewy, J. W., Ehrich, E. W., & Vivitrex Study Group, F. T. (2005) · JAMA · doi:10.1001/jama.293.13.1617 · Cited by 635
Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms
HEILIG, M., & EGLI, M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.02.001 · Cited by 377
Treatment of substance abusing patients with comorbid psychiatric disorders
Kelly, T. M., Daley, D. C., & Douaihy, A. B. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.09.010 · Cited by 284
Addiction as a brain disease revised: why it still matters, and the need for consilience
(2021) · doi:10.1038/s41386-020-00950-y · Cited by 290
Pharmacogenetic approaches to the treatment of alcohol addiction
Heilig, M., Goldman, D., Berrettini, W., & O'Brien, C. P. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3110 · Cited by 248
Metadata
- Authors
- Mark, T.
- Corresponding author
- Mark, T
- ORCID
- Mark, T
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2003-09-10
- Volume
- 71
- Issue
- 3
- Pages
- 219-228
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W2161761640
- Cited by
- 120
- References
- 41
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 2 · 2021: 5 · 2020: 4 · 2019: 6 · 2018: 4 · 2017: 4 · 2016: 6 · 2015: 5 · 2014: 5 · 2013: 5 · 2012: 5
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Drug and Alcohol Dependence (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01aa012146-02)
- National Institute on Alcohol Abuse and Alcoholism (K24 AA13736, R01-AA12146-01A1, K24AA013736)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- naltrexone, prescription rates, alcoholism treatment, medication adherence, patient refusal, drug affordability, barriers to prescribing
- MeSH terms
- Data Collection, Humans, Naltrexone, Patient Compliance, Physicians, Drug Prescriptions, United States, Multivariate Analysis, Logistic Models, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Understanding US addiction physicians' low rate of naltrexone prescription. https://app.cochat.ai/papers/10.1016/s0376-8716(03)00134-0
- The paper
- Mark, T. (2003). Understanding US addiction physicians' low rate of naltrexone prescription. Drug and Alcohol Dependence. https://doi.org/10.1016/s0376-8716(03)00134-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.